Floyd Underhill, MD
Family Medicine · Edmond, OKNPI 1194792747
Payments from drug & device makers
Across 231 payments — averaging $15.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$939
- Lilly USA, LLC$301
- Novo Nordisk$301
- Pfizer$277
- Takeda Pharmaceuticals U.S.A., Inc.$195
- Merck$161
- plus $1K from 31 others
What the payments were for
- Food & beverage$3,568100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 55 | $939 |
| Lilly USA, LLC | 21 | $301 |
| Novo Nordisk | 22 | $301 |
| Pfizer | 23 | $277 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $195 |
| Merck | 11 | $161 |
| Abbott | 9 | $157 |
| GSK | 7 | $99 |
| Inogen, Inc. | 8 | $86 |
| Amgen | 6 | $79 |
| Novartis | 5 | $78 |
| Antares Pharma, Inc. | 5 | $77 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $67 |
| Dynavax Technologies Corporation | 5 | $60 |
| Genentech USA, Inc. | 4 | $59 |
| Philips North America LLC | 1 | $53 |
| Sanofi-aventis U.S. LLC | 4 | $53 |
| AstraZeneca | 3 | $51 |
| Amarin Pharma, Inc. | 3 | $50 |
| Sanofi Pasteur Inc. | 3 | $43 |
| Johnson & Johnson | 2 | $39 |
| Astellas Pharma US Inc | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Exact Sciences | 2 | $31 |
| Esperion Therapeutics, Inc. | 2 | $27 |
| Boehringer Ingelheim | 2 | $26 |
| Medtronic | 1 | $25 |
| Harmony Biosciences LLC | 1 | $22 |
| Mayne Pharma Commercial LLC | 1 | $22 |
| Therapeuticsmd, Inc. | 1 | $18 |
| Halozyme Inc | 1 | $16 |
| Abiomed | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Azurity Pharmaceuticals, Inc. | 1 | $13 |
| Upsher-smith Laboratories LLC | 1 | $13 |
How this compares
$3,568 in reported general payments places this provider in the 80th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 138 | $150,325 |
| EliquisApixaban | 95 | $86,572 |
| MounjaroTirzepatide | 22 | $33,776 |
| MyrbetriqMirabegron | 45 | $32,747 |
| JardianceEmpagliflozin | 40 | $32,526 |
| FarxigaDapagliflozin Propanediol | 27 | $24,201 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $20,608 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $15,656 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $9,150 |
| JanuviaSitagliptin Phosphate | 13 | $6,866 |
| BelsomraSuvorexant | 18 | $5,061 |
| Atorvastatin Calcium | 310 | $4,275 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,260 |
| Advair DiskusFluticasone Propion/Salmeterol | 24 | $4,209 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $3,356 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $301 | $150,325138 claims |
| PfizerEliquis | $277 | $86,57295 claims |
| Lilly USA, LLCMounjaro | $301 | $33,77622 claims |
| Astellas Pharma US IncMyrbetriq | $34 | $32,74745 claims |
| Boehringer IngelheimJardiance | $26 | $32,52640 claims |
| AstraZenecaFarxiga | $51 | $24,20127 claims |
| MerckJanumet, Januvia, Belsomra | $161 | $21,07742 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $99 | $19,91535 claims |
| AbbVieSynthroid | $939 | $2,04131 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Edmond
- Stanley ShadidEdmond$363K
- Susan DimickEdmond$256K
- Charles WoodwardEdmond$15K
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.